CEO & Chairman Discloses 59.53% Controlling Stake Post-SPAC Merger
SLBT sits 84% above its 52-week low of $3.
Summary
Ching-Dong Wang, CEO and Chairman, along with affiliated entities, disclosed a 59.53% beneficial ownership in SL Science Holding Ltd. following the completion of its business combination on June 12, 2026.
Key Events · Ownership and Investor Activity · SLBT
-
Controlling Ownership Established
Ching-Dong Wang and his affiliated entities now beneficially own 333,832,129 ordinary shares, representing 59.53% of the company's outstanding stock.
-
Post-Merger Disclosure
This significant ownership stake was acquired as a result of the business combination (SPAC merger) completed on June 12, 2026, which saw SL Bio merge with Horizon Space Acquisition II Corp.
-
Leadership Role
Ching-Dong Wang serves as the Chief Executive Officer, Director, and Chairman of the Board of SL Science Holding Ltd.
Analysis · SLBT · Life Sciences
This Schedule 13D filing is critical as it formally discloses that Ching-Dong Wang, the CEO and Chairman, holds a controlling majority stake in SL Science Holding Ltd. immediately following its recent SPAC merger. This establishes the governance structure and the significant personal investment of the company's top executive. This disclosure is particularly important given the concurrent 20-F filing which revealed "going concern" issues, meaning the company's future is uncertain under this new leadership and ownership structure.
At the time of this filing, SLBT was trading at $5.52 on NASDAQ in the Life Sciences sector. The 52-week trading range was $3.00 to $14.50. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.